



Neuren Senior Scientist inducted into prestigious US Institute of Medicine

Wednesday 9 November 2005: Neuren Pharmaceuticals (ASX: NEU) today announced its Chief Scientific Officer, Professor Peter D Gluckman FRS, has been inducted into the Institute of Medicine (IOM) of the US National Academies of Sciences in Washington D.C. at its annual meeting last week.

The IOM is one of the three academies of the prestigious National Academies of Science in the United States that include among its members 180 Nobel Laureates. It was established in 1970 by the National Academy of Sciences to honour professional achievement in the health sciences and to serve as a national resource for independent analysis and recommendations on issues related to medicine, biomedical sciences, and health.

Professor Gluckman is the first New Zealander to be honoured by the IOM and only the second Australasian, the only other being the recent Nobel Laureate, Professor Barry Marshall.

Election to IOM membership by peers in the medical fields recognises those who have made major contributions to the advancement of the medical sciences, health care, and public health. It is considered one of the highest honours in these fields. There are only 79 foreign members of the Institute with a maximum of five being elected each year.

Mr David Clarke, CEO of Neuren commented: "We are thrilled that our founding scientist has received international recognition for his contributions to medicine and research, some of which forms the basis of Neuren's scientific and development programs."

About Neuren Pharmaceuticals

Neuren Pharmaceuticals (ASX: NEU) is a biopharmaceutical company developing novel therapeutics in the fields of neural repair and rescue and metabolic disorders. The Neuren portfolio consists of six product families, targeting markets with large unmet needs and limited competition. Neuren has two lead clinical candidates, Glypromate® and NNZ-2566, presently in development to treat a range of acute neurological conditions. Neuren has commercial and development partnerships, including with Pfizer, the US Army's Walter Reed Army Institute of Research and Metabolic Pharmaceuticals.

For more information, please visit Neuren's website at www.neurenpharma.com

Contact details

Company	Media and investor relations
David Clarke CEO of Neuren T: 1800 259 181 (Australia) T: +64 9 3 367 7167 ext 82308 (New Zealand) M: +64 21 988 052	Rebecca Piercy Buchan Consulting T: +61 3 9866 4722 M: +61 422 916 422